Merck & Co Inc (MRK)

64.92
0.12 0.18
NYSE : Health Care
Prev Close 65.04
Open 65.00
Day Low/High 64.82 / 65.20
52 Wk Low/High 55.10 / 66.80
Volume 3.69M
Avg Volume 8.99M
Exchange NYSE
Shares Outstanding 2.74B
Market Cap 177.90B
EPS 1.40
P/E Ratio 41.43
Div & Yield 1.88 (2.90%)

Latest News

I Can't Swallow the 'Plunge Team'

If it limits volatility, how has the market fallen?

Merck Declares 47 Cent Quarterly Dividend

Merck Declares 47 Cent Quarterly Dividend

The dividend will be paid on July 10 to shareholders of record at the close of business on June 15.

47 Quarterly Dividend Declared By Merck

47 Quarterly Dividend Declared By Merck

Merck , said today that its board of directors authorized a quarterly dividend of 47 cents

Merck Announces Third-Quarter 2017 Dividend

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the Board of Directors has declared a quarterly dividend of $0.

Broker Darlings of the Dow: Merck Ranks As a Top 15 Analyst Pick

A study of analyst recommendations at the major brokerages shows that Merck & Co Inc is the #6 broker pick, on average, out of the 30 stocks making up the Dow Jones Industrial Average, according to ETF Channel. Merck & Co Inc also comes in above the median of analyst picks among the broader S&P 500 index components, claiming the #127 spot out of 500.

Merck & Co Faces Financial Hit From U.K. Regulator Over Drug Pricing

Merck & Co Faces Financial Hit From U.K. Regulator Over Drug Pricing

Merck & Co may face financial penalties from U.K. regulators after the Competition & Markets Authority released provisional findings of a drug pricing investigation into the American drugmaker.

Merck Announces Presentation Of Phase 2 Results For MK-7264, An Investigational, P2X3 Receptor Antagonist, Being Evaluated For The Treatment Of Chronic Cough

Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the presentation of results from a Phase 2 study evaluating the safety, efficacy and therapeutic dose range of MK-7264 (formerly...

Merck Receives CHMP Positive Opinion Recommending Approval Of ISENTRESS® (raltegravir) 600 Mg In The European Union

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)...

100 Healthy Years - Are Kids Prepared?

Wall Street Makes a Comeback as Walmart Distracts From Trump Troubles

Wall Street Makes a Comeback as Walmart Distracts From Trump Troubles

Wall Street snaps back to gains on Thursday as positive earnings from Walmart help distract from brewing trouble in Washington, D.C.

FDA Approves Merck's KEYTRUDA® (pembrolizumab) For Certain Patients With Locally Advanced Or Metastatic Urothelial Carcinoma, A Type Of Bladder Cancer

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.

Cramer: Let Loose the Growth Hounds

Cramer: Let Loose the Growth Hounds

Day 2 of the selloff brings in an entirely new kind of buyer.

Stocks Add to Gains as Walmart, Health Care Drive Market Comeback

Stocks Add to Gains as Walmart, Health Care Drive Market Comeback

Stocks add to gains on Thursday, coming back from their worst losses in eight months a day earlier, as a positive quarter for Walmart boosts consumer names.

Incyte Shares Vault After 'IDO' Cancer Immunotherapy Combo Data Revealed

Incyte Shares Vault After 'IDO' Cancer Immunotherapy Combo Data Revealed

The new Incyte data revealed ahead of the ASCO meeting in June involve combination therapies with Merck and Bristol-Myers Squibb in multiple types of cancer.

Stocks Turn Higher as Walmart, Health Care Overshadow Trump Trouble

Stocks Turn Higher as Walmart, Health Care Overshadow Trump Trouble

Stocks turn higher as Walmart does the heavy lifting on the Dow and S&P 500, and health care gives a boost to the Nasdaq.

Biotech Movers: Fast Track Designation Sends Sage Shares Higher

Biotech Movers: Fast Track Designation Sends Sage Shares Higher

Sage Therapeutics, Incyte and Shire were among the biotech movers in premarket trading on Thursday.

Merck KGaA Edges Full-Year Guidance Higher After Solid Q1 Earnings

Merck KGaA Edges Full-Year Guidance Higher After Solid Q1 Earnings

Merck KGaA posted slightly stronger-than-expected first quarter earnings Thursday and nudged its full-year profit guidance higher after a key drug approval in the United States.

Merck Keytruda-Chemo ASCO '17 Update Shows Lung Cancer Survival Trend

Merck Keytruda-Chemo ASCO '17 Update Shows Lung Cancer Survival Trend

The new Merck survival data were included in a research abstract for next month's American Society of Clinical Oncology (ASCO) annual meeting that was distributed on Wednesday night.

Data For KEYTRUDA® (pembrolizumab) Across 16 Types Of Cancer From Merck's Industry-Leading Immuno-Oncology Program To Be Presented At The 2017 ASCO Annual Meeting

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that new and updated data from studies of KEYTRUDA ® (pembrolizumab), the company's anti-PD-1 therapy, will be presented at the 53 rd...

Aduro Biotech, Merck Team on Cancer Drug Trial

Aduro Biotech, Merck Team on Cancer Drug Trial

Aduro Biotech and Merck will team on two separate trials featuring Aduro's CRS-207 and Merck's Keytruda to explore treatments for mesothelioma and gastric cancer.

Jim Cramer -- Citi's Downgrade of Pfizer Not Totally Reasonable

Jim Cramer -- Citi's Downgrade of Pfizer Not Totally Reasonable

Citigroup had a 'thoughtful' research piece on Pfizer, but downgrading it partly based on 'transaction risk' seems unreasonable, Cramer said.

Merck To Present New Phase 3 Data On Investigational Ertugliflozin, Additional Analyses Of Studies Of JANUVIA® (sitagliptin), And Real-World Evidence Research At The 77th Scientific Sessions Of The American Diabetes Association

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that 19 scientific presentations from Merck's diabetes pipeline and portfolio - including Phase 3 data for investigational ertugliflozin,...

Closing Bell: Snap Sells Off After Weak Quarter; Macy's, Kohl's Sink Wall Street

Closing Bell: Snap Sells Off After Weak Quarter; Macy's, Kohl's Sink Wall Street

Stocks hold losses as a selloff in Snap pulls the rest of the tech sector lower.

Snap, Retailers Sell Off on Earnings Disappointments; Nasdaq on Track to End Record Streak

Snap, Retailers Sell Off on Earnings Disappointments; Nasdaq on Track to End Record Streak

Stocks hold modest losses on Thursday as a selloff in Snap pulls the rest of the tech sector lower, while Macy's leads other retailers lower.